达比加群在房颤成人患者中的剂量方案:真实世界肾功能范围的压力测试
该研究基于超过9000例临床试验患者建立的人群药代动力学模型进行模拟,比较达比加群药品说明书剂量与其他 proposed 剂量方案在肌酐清除率15-250 mL/min范围内维持谷浓度75-150 ng/mL的治疗范围的表现。结果识别出一个需要五种不同给药方案(对应特定肾功能范围)的改进方案,优于说明书中的两种批准方案。
要点
- 达比加群疗效与安全性同稳态血浆浓度相关,但剂量-浓度关系变异大。
- 模拟显示改进方案需按肾功能范围采用五种给药方案,而非说明书两种。
- 目标治疗谷浓度为75-150 ng/mL,覆盖肌酐清除率15-250 mL/min。
核心结论
- 基于人群药代动力学模拟,识别出一个能更好达到治疗谷浓度范围的改进达比加群给药方案,需五种给药方案对应特定肾功能范围。
研究设计与样本
- 基于超过9000例临床试验患者的人群药代动力学模型进行模拟,比较说明书剂量与其他 proposed 剂量方案。
主要发现
- 在肌酐清除率15-250 mL/min范围内模拟谷浓度,评估各方案维持75-150 ng/mL治疗范围的表现。
- 改进方案需五种给药方案对应特定肾功能范围,而说明书仅批准两种。
关键数值与推荐
- 治疗谷浓度范围为75-150 ng/mL。
- 模拟的肾功能范围为肌酐清除率15-250 mL/min。
- 改进方案需五种给药方案,对应特定肾功能范围。
临床怎么用
- 提示临床可依据肾功能范围细化达比加群剂量选择,以更稳定维持治疗谷浓度。
局限性
- 结果为基于药代动力学模型的模拟,非真实世界临床结局验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dabigatran is the first of four direct-acting oral anticoagulants approved to prevent stroke in adult patients with atrial fibrillation using a fixed two-dose scheme compared with warfarin dosing adjusted to a prothrombin time range associated with optimal risk reduction in stroke and serious bleeding. The pivotal phase III trial found dabigatran, depending on dose, is superior to warfarin in stroke reduction and similar in bleeding risk while also showing dabigatran efficacy and safety correlate with steady-state plasma concentrations. Because the relationship between dabigatran dose and plasma concentration is highly variable, a previously developed population pharmacokinetic model of over 9,000 clinical trial patients was used as a basis for simulations comparing the performance of dosing via the drug label to other proposed doses and regimens. Assessment of dosing regimen performance was based on simulations of trough plasma levels within the therapeutic concentration range of 75-150 ng/mL over a renal function range of 15-250 mL/min creatinine clearance, representing extremes for real-world patients. An improved regimen that best achieves this therapeutic range was identified, requiring five different dosing schedules, corresponding to specified renal function ranges, compared with the two approved in the label. The discussion focuses on how this information could better inform patient outcomes and future dabigatran development.
引用
- Powell JR, Al Qaraghuli F, Fiedler-Kelly J, et al. Dabigatran Dosing Proposal for Adults With Atrial Fibrillation: Stress-Testing Renal Function Range in Real World Patients. Clin Pharmacol Ther. 2023. PMID: 37026424. doi:10.1002/cpt.2902
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。